Use of biomarkers in ALS drug development and clinical trials

Brain Research

Volumn 1607, Issue , 2015, Pages 94-107

  Bakkar, Nadine ^a   Boehringer, Ashley ^a   Bowser, Robert ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

ALS; Biomarkers; Clinical trial; Pharmacodynamic biomarker; Prognostic biomarker

Indexed keywords

AMINO ACID; ANTISENSE OLIGONUCLEOTIDE; AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYSTATIN C; CYTOSKELETON PROTEIN; FINGOLIMOD; GRANZYME B; HIGH MOBILITY GROUP B1 PROTEIN; MEMANTINE; N ACETYLASPARTIC ACID; PEPTIDE; PHARMACODYNAMIC BIOMARKER; PHOSPHATE; PIOGLITAZONE; PROGNOSTIC BIOMARKER; PROTEIN NOGO A; PROTEIN S100B; PYRIMETHAMINE; RETINOIC ACID; RNA BINDING PROTEIN; SEROTONIN; SERUM ALBUMIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; URATE;

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD; BRAIN METABOLISM; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; DEATH; DISEASE COURSE; DRUG EFFICACY; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC MARKER; HUMAN; IMMUNE SYSTEM; MASS SPECTROMETRY; MICROGLIA; MONOCYTE; MULTIPLE SCLEROSIS; MUSCLE; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN CEREBROSPINAL FLUID LEVEL; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT RESPONSE; ANIMAL; DRUG DEVELOPMENT; METABOLISM; PROCEDURES; PROGNOSIS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; PROGNOSIS;

EID: 84926176151     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2014.10.031     Document Type: Review

References (136)

1. S.W. Ahn Motor unit number estimation in evaluating disease progression in patients with amyotrophic lateral sclerosis J Korean Med. Sci. 25 2010 1359 1363
2. S. Almeida Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons Acta Neuropathol. 126 2013 385 399
3. C. Armon, and M.E. Brandstater Motor unit number estimate-based rates of progression of ALS predict patient survival Muscle Nerve 22 1999 1571 1575
4. I.M. Arts Muscle ultrasonography to predict survival in amyotrophic lateral sclerosis J. Neurol. Neurosurg. Psychiatry. 82 2011 552 554
5. P.E. Ash Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS Neuron 77 2013 639 646
6. V. Askanas, S. Woicik, and W.K. Engel Expression of Nogo-A in human muscle fibers is not specific for amyotrophic lateral sclerosis Ann. Neurol. 62 2007 676
7. M. Basso Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: Implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis J. Biol. Chem. 288 2013 15699 15711
8. D.R. Beers Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis Brain 134 2011 1293 1314
9. F. Bi Reactive astrocytes secrete lcn2 to promote neuron death Proc. Natl. Acad. Sci. U.S.A. 110 2013 4069 4074
10. H. Blasco Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis J. Neurol. Sci. 303 2011 124 127
11. H. Blasco Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry J. Proteome Res. 12 2013 3746 3754
12. K. Blennow, H. Hampel, and H. Zetterberg Biomarkers in amyloid-beta immunotherapy trials in Alzheimer's disease Neuropsychopharmacology 39 2014 189 201
13. K. Boylan Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker J. Neurochem. 111 2009 1182 1191
14. K.B. Boylan Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis J. Neurol. Neurosurg. Psychiatry. 84 2013 467 472
15. M.E. Bozik A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS Amyotroph Lateral Scler Frontotemporal Degener 15 2014 406 413
16. M.F. Burkhardt A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells Mol. Cell Neurosci. 56 2013 355 364
17. O. Butovsky Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS J. Clin. Invest. 122 2012 3063 3087
18. S. Byrne Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study Lancet Neurol. 11 2012 232 240
19. A.C. Calvo Genetic biomarkers for ALS disease in transgenic SOD1G93A mice PLoS One 7 2012 e32632 10.1371/journal.pone.0032632
20. H. Chen Modeling ALS with iPSCs Reveals that Mutant SOD1 Misregulates Neurofilament Balance in Motor Neurons Cell Stem Cell. 14 2014 796 809
21. Chen, X., et al., 2014b. An exploratory study of serum creatinine levels in patients with amyotrophic lateral sclerosis. Neurol. Sci.
22. A. Chio UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study Neurobiol. Aging. 34 357 2013 (e1-5)
23. A. Chio Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study JAMA Neurol. 71 2014 1134 1142
24. I.M. Chiu T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS Proc. Natl. Acad. Sci. U.S.A. 105 2008 17913 17918
25. I.M. Chiu A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model Cell Rep. 4 2013 385 401
26. J.K. Choi Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation Eur. J. Neurosci. 30 2009 2143 2150
27. Diekstra, F.P., et al., 2012. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol. Aging. 33, 630 e3-8.
28. J.T. Dimos Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons Science 321 2008 1218 1221
29. C.J. Donnelly RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention Neuron 80 2013 415 428
30. T. Dunckley Whole-genome analysis of sporadic amyotrophic lateral sclerosis N. Engl. J. Med. 357 2007 775 788
31. L. Dupuis Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis Neurobiol. Dis. 10 2002 358 365
32. L. Dupuis Platelet serotonin level predicts survival in amyotrophic lateral sclerosis PLoS One 5 2010 e13346
33. N. Egawa Drug screening for ALS using patient-specific induced pluripotent stem cells Sci. Transl. Med 4 2012 (145ra104)
34. M.C. Evans T(2)-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS J. Cereb. Blood Flow Metab. 34 2014 785 793
35. E. Feneberg Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases Amyotroph Lateral Scler Frontotemporal Degener 15 2014 351 356
36. S.A. Fernandes Oligonucleotide-based therapy for FTD/ALS Caused by the C9orf72 repeat expansion: a perspective J. Nucleic Acids 2013 2013 208245
37. M. Fiala Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients Am. J. Neurodegener. Dis. 2 2013 129 139
38. J. Ganesalingam Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS J. Neurochem. 117 2011 528 537
39. J. Ganesalingam pNfH is a promising biomarker for ALS Amyotroph Lateral Scler Frontotemporal Degener 14 2013 146 149
40. N. Ghasemzadeh, F. Nyberg, and S. Hjerten Highly selective artificial gel antibodies for detection and quantification of biomarkers in clinical samples. II. Albumin in body fluids of patients with neurological disorders J. Sep. Sci. 31 2008 3954 3958
41. P.H. Gordon Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience Neurodegener. Dis. 12 2013 81 90
42. M. Grossman Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis JAMA Neurol. 71 2014 442 448
43. A.M. Haidet-Phillips Astrocytes from familial and sporadic ALS patients are toxic to motor neurons Nat. Biotechnol. 29 2011 824 828
44. A. Hashizume Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy Brain 135 2012 2838 2848
45. K. Hensley Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis J. Neurochem. 82 2002 365 374
46. B. Heurich Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis J. Neuroimmunol. 235 2011 104 109
47. D.R. Hodgson Biomarkers in oncology drug development Mol. Oncol. 3 2009 24 32
48. C.S. Hwang Elevated serum autoantibody against high mobility group box 1 as a potent surrogate biomarker for amyotrophic lateral sclerosis Neurobiol. Dis. 58 2013 13 18
49. K. Ikeda Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study Intern. Med. 51 2012 1501 1508
50. J. Ilzecka Granzymes A and B levels in serum of patients with amyotrophic lateral sclerosis Clin. Biochem. 44 2011 650 653
51. F.J. Jimenez-Jimenez Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis Acta Neurol. Scand. 111 2005 114 117
52. N. Jokic Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity Ann. Neurol. 57 2005 553 556
53. E.J. Kasarskis Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study J. Neurol. Sci. 130 1995 203 208
54. D. Keizman Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis Acta Neurol. Scand. 119 2009 383 389
55. Keller, M.F., et al., 2014. Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. JAMA Neurol.
56. L.C. Kudo Integrative gene-tissue microarray-based approach for identification of human disease biomarkers: application to amyotrophic lateral sclerosis Hum. Mol. Genet. 19 2010 3233 3253
57. J. Kuhle Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis Eur. J. Neurol 16 2009 771 774
58. A. Kumar Metabolomic analysis of serum by (1)H NMR spectroscopy in amyotrophic lateral sclerosis Clin. Chim. Acta. 411 2010 563 567
59. J.E. Landers Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis Proc. Natl. Acad. Sci. U.S.A. 106 2009 9004 9009
60. D.J. Lange Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study Amyotroph Lateral Scler Frontotemporal Degener 14 2013 199 204
61. K.A. Lawton Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics Amyotroph Lateral Scler Frontotemporal Degener 2014 1 9
62. Leblond, C.S., et al., 2014. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol.
63. C.D. Lee Muscle ultrasound quantifies the rate of reduction of muscle thickness in amyotrophic lateral sclerosis Muscle Nerve. 42 2010 814 819
64. J.D. Lee Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis J. Neuroinflamm. 10 2013 119
65. S. Lehnert Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis Amyotroph Lateral Scler Frontotemporal Degener 15 2014 344 350
66. T.D. Levine A pilot trial of memantine and riluzole in ALS: Correlation to CSF biomarkers Amyotroph Lateral Scler. 11 2010 514 519
67. T.D. Levine A pilot trial of pioglitazone HCl and tretinoin in ALS: cerebrospinal fluid biomarkers to monitor drug efficacy and predict rate of disease progression Neurol. Res. Int 2012 2012 582075
68. J. Li, M. Sung, and S.B. Rutkove Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice PLoS One 8 2013 e65976
69. E. Lilo Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1G93A mouse model Hum. Mol. Genet. 22 2013 4720 4725
70. J.M. Lincecum From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis Nat. Genet. 42 2010 392 399
71. A. Lopez-Lopez CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis PLoS One 9 2014 e96528
72. C.H. Lu Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1G93A mice that model ALS PLoS One 7 2012 e40998 10.1471/journal.pone.0040998
73. E. Majounie Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study Lancet Neurol. 11 2012 323 330
74. S. Mantovani Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process J. Neuroimmunol. 210 2009 73 79
75. G. Marc Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice BioMed. Res. Int 2013 2013 845345
76. S. Marcuzzo Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: a longitudinal MRI study Exp. Neurol. 231 2011 30 37
77. P. McGoldrick Rodent models of amyotrophic lateral sclerosis Biochim. Biophys. Acta. 1832 2013 1421 1436
78. V. Meininger Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial PLoS One 9 2014 e97803
79. R.G. Miller NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study Amyotroph Lateral Scler Frontotemporal Degener 2014 1 9
80. T.M. Miller Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis Ann. Neurol. 57 2005 773 776
81. T.M. Miller An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study Lancet Neurol. 12 2013 435 442
82. R.M. Mitchell A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis Neurology 72 2009 14 19
83. R.M. Mitchell Plasma biomarkers associated with ALS and their relationship to iron homeostasis Muscle Nerve 42 2010 95 103
84. A.T. Mizwicki Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling Am. J. Neurodegener. Dis. 1 2012 305 315
85. K. Mori Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins Acta Neuropathol. 126 2013 881 893
86. S.T. Ngo The relationship between Bayesian motor unit number estimation and histological measurements of motor neurons in wild-type and SOD1(G93A) mice Clin. Neurophysiol. 123 2012 2080 2091
87. Y. Noto Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: Specificity, sensitivity, and a possible prognostic value Amyotroph Lateral Scler. 12 2011 140 143
88. S. Paganoni Uric acid levels predict survival in men with amyotrophic lateral sclerosis J. Neurol. 259 2012 1923 1928
89. S. Pillen, I.M. Arts, and M.J. Zwarts Muscle ultrasound in neuromuscular disorders Muscle Nerve. 37 2008 679 693
90. P.F. Pradat Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes Ann. Neurol. 62 2007 15 20
91. F. Puentes Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis J. Neurol. Neurosurg. Psychiatry. 85 2014 274 278
92. G.S. Ralph Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model Nat. Med. 11 2005 429 433
93. S. Rani Isolation of exosomes for subsequent mRNA, microRNA, and protein profiling Methods Mol. Biol. 784 2011 181 195
94. C. Raoul Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS Nat. Med. 11 2005 423 428
95. J.M. Ravits, and A.R. La Spada ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration Neurology 73 2009 805 811
96. A.G. Reaume Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury Nat. Genet. 13 1996 43 47
97. A.E. Renton A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD Neuron 72 2011 257 268
98. A.E. Renton, A. Chio, and B.J. Traynor State of play in amyotrophic lateral sclerosis genetics Nat. Neurosci. 17 2014 17 23
99. M. Rentzos Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol. Scand 125 2012 260 264
100. G. Riboldi Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases Mol. Neurobiol. 2014
101. L. Robelin, and Gonzalez De Aguilar, J.L. Blood biomarkers for amyotrophic lateral sclerosis: myth or reality? Biomed. Res. Int. 2014 525097
102. S. Rutkove Electrical impedance myography as a biomarker for ALS Lancet Neurol. 8 2009 226 (author reply 227)
103. S.B. Rutkove Electrical impedance myography as a biomarker to assess ALS progression Amyotroph Lat. Scler. 13 2012 439 445
104. S.B. Rutkove Electrical impedance myography correlates with standard measures of ALS severity Muscle Nerve. 49 2014 441 443
105. D. Sareen Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion Sci. Transl. Med. 5 2013 208ra149
106. M. Saresella T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis Clin. Immunol. 148 2013 79 88
107. R. Sattler Human nasal olfactory epithelium as a dynamic marker for CNS therapy development Exp. Neurol. 232 2011 203 211
108. S. Scott Design, power, and interpretation of studies in the standard murine model of ALS Amyotroph Lat. Scler 9 2008 4 15
109. T. Sekiguchi Spreading of amyotrophic lateral sclerosis lesions-multifocal hits and local propagation? J. Neurol. Neurosurg. Psychiatry 85 2013 85 91
110. J.M. Shefner, M. Cudkowicz, and R.H. Brown Jr. Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis Muscle Nerve. 34 2006 603 607
111. J.M. Shefner Multipoint incremental motor unit number estimation as an outcome measure in ALS Neurology 77 2011 235 241
112. R. Simon, and S. Roychowdhury Implementing personalized cancer genomics in clinical trials Nat. Rev. Drug Discovery 12 2013 358 369
113. M. Sta Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation Neurobiol. Dis. 42 2011 211 220
114. X.W. Su Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis JAMA Neurol. 70 2013 1505 1511 10.1001/jamaneurol.2013.4646
115. Z. Su Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS Neuron 83 2014 1043 1050
116. S.D. Sussmuth Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum Neurosci. Lett. 353 2003 57 60
117. S.D. Sussmuth CSF glial markers correlate with survival in amyotrophic lateral sclerosis Neurology 74 2010 982 987
118. S. Tagerud, R. Libelius, and C. Magnusson Muscle Nogo-A: a marker for amyotrophic lateral sclerosis or for denervation? Ann. Neurol 62 2007 676
119. S. Tetsuka ZNF512B gene is a prognostic factor in patients with amyotrophic lateral sclerosis J. Neurol. Sci. 324 2013 163 166
120. S. Tetsuka Creatinine/cystatin C ratio as a surrogate marker of residual muscle mass in amyotrophic lateral sclerosis Neurol. Clin. Neurosci 1 2013 32 37
121. R. Tortelli Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression Eur. J. Neurol 19 2012 1561 1567
122. B.J. Traynor Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients Proc. Natl. Acad. Sci. U.S.A. 107 2010 12335 12338
123. I. Vaknin Excess circulating alternatively activated myeloid (M2) cells accelerate ALS progression while inhibiting experimental autoimmune encephalomyelitis PLoS One 6 2011 e26921 10.1371/journal.pone.002692
124. P.T. van Doormaal Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study Neurobiol. Aging. 2014
125. M.A. van Es Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis Nat. Genet. 40 2008 29 31
126. M.A. van Es Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis Nat. Genet. 41 2009 1083 1087
127. A. Van Hoecke EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans Nat. Med. 18 2012 1418 1422
128. E. Verstraete TDP-43 plasma levels are higher in amyotrophic lateral sclerosis Amyotroph Lateral Scler. 13 2012 446 451
129. N. von Neuhoff Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic PLoS One 7 2012 e44401 10.1371/journal.pone.0044401
130. S. Vucic, G.A. Nicholson, and M.C. Kiernan Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis Brain 131 2008 1540 1550
131. L.L. Wang Electrical impedance myography for monitoring motor neuron loss in the SOD1 G93A amyotrophic lateral sclerosis rat Clin. Neurophysiol. 122 2011 2505 2511
132. M.E. Wilson, I. Boumaza, and R. Bowser Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis PLoS One 5 2010 e15133 10.1371/journal.pone.0015133
133. L. Winer SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy JAMA Neurol 70 2013 201 207
134. T.M. Woodruff The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis J Immunol. 181 2008 8727 8734
135. W. Zhao Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms Neurobiol. Dis. 48 2012 418 428
136. T. Zu RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia Proc. Natl. Acad. Sci. U.S.A. 110 2013 E4968 E4977